| Vol. 14.18 – 10 May, 2022 |
| |
|
|
Fibrillin-1 Regulates White Adipose Tissue Development, Homeostasis, and Function | To elucidate the fibrillin-1-dependent adipogenic mechanisms in cell culture, researchers used primary bone marrow-derived MSCs from Fbn1mgR/mgR, Fbn1C1041G/+ and wild-type mice. [Matrix Biology] |
|
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
Identification of Distinct Non-Myogenic Skeletal-Muscle-Resident Mesenchymal Cell Populations | Investigators identified six distinct Pdgfra+ non-myogenic muscle-resident mesenchymal cell populations that fit within a bipartite differentiation trajectory from a common progenitor. [Cell Reports] |
|
|
|
MDS Cells Impair Osteolineage Differentiation of MSCs via Extracellular Vesicles to Suppress Normal Hematopoiesis | The authors demonstrated that both human and mouse myelodysplastic syndrome (MDS) cells perturbed bone metabolism by suppressing the osteolineage differentiation of MSCs, which impaired the ability of MSCs to support normal hematopoietic stem cells. [Cell Reports] |
|
|
|
Adipose Tissue-Derived Mesenchymal Stem Cells’ Acellular Product Extracellular Vesicles as a Potential Therapy for Crohn’s Disease | Considering the critical roles of macrophage polarization in Crohn’s disease and immunomodulatory properties of MSCs, scientists deciphered the interaction between adipose-derived MSCs and macrophages, including their cytokine production, regulation of differentiation, and pro-/anti-inflammatory function. [Journal of Cellular Physiology] |
|
|
|
Wnt/β-Catenin Signaling Pathway Is Involved in Early Dopaminergic Differentiation of Trabecular Meshwork-Derived Mesenchymal Stem Cells | To examine if Wnt/beta-catenin pathway drives trabecular meshwork-derived MSCs towards a dopaminergic fate, investigators treated them with the Wnt agonist and the Wnt antagonist. [Journal of Cellular Biochemistry] |
|
|
|
Extracellular Vesicles Derived from Human Bone Marrow Mesenchymal Stem Cells Protect Rats against Acute Myocardial Infarction-Induced Heart Failure | Scientists explored the underlying mechanism of bone marrow MSCs-extracellular vesicles in acute myocardial infarction-induced heart failure. [Cell and Tissue Research] |
|
|
|
Loss of KDM4B Impairs Osteogenic Differentiation of OMSCs and Promotes Oral Bone Aging | Investigators found that the histone demethylase KDM4B played an essential role in regulating the osteogenesis of MSCs isolated from oral bones and oral bone aging. [International Journal of Oral Science] |
|
|
|
Conditioned Medium from Amniotic Fluid Mesenchymal Stem Cells Could Modulate Alzheimer’s Disease-Like Changes in Human Neuroblastoma Cell Line Sy-SY5Y in a Paracrine Manner | Researchers investigated the paracrine effect of amniotic fluid-derived MSCs on Alzheimer’s disease changes in human SH–SY5Y cells. [Tissue and Cell] |
| |
|
|
Conductive Nanocomposite Hydrogel and Mesenchymal Stem Cells for the Treatment of Myocardial Infarction and Non-Invasive Monitoring via Pet/Ct | The combination of MSCs and the injectable conductive nanocomposite hydrogel offered a promising strategy for myocardial infarction treatment. [Journal of Nanobiotechnology] |
|
|
|
Mesh-Like Electrospun Membrane Loaded with Atorvastatin Facilitates Cutaneous Wound Healing by Promoting the Paracrine Function of Mesenchymal Stem Cells | Scientists established a rat model of wound healing, applied atorvastatin -loaded mesh-like membranes seeded with bone marrow-derived MSCs on wounds, and assessed their efficacy for promoting wound healing. [Stem Cell Research & Therapy] |
| |
|
|
|
Mesenchymal Stromal Cells (MSCs) and Their Exosome in Acute Liver Failure (Alf): A Comprehensive Review | The authors discuss recent progress in preclinical and clinical studies and current challenges in MSCs-based therapies in acute liver failure, with a special focus on in vivo reports. [Stem Cell Research & Therapy] |
|
|
|
|
Umoja Biopharma Announces Activation of First ENLIGHTen Phase I Trial Site in Study of UB-TT170, a TumorTag that Targets Folate Receptors to Mark Tumors for Clearance by CAR T Cells | Umoja Biopharma, Inc. announced the Seattle Children’s activation of the Phase I ENLIGHTen clinical trial in patients with osteosarcoma to assess the safety and tolerability of autologous “universal” CAR T cells when administered with UB-TT170, the company’s proprietary small molecule fluorescein tag. [Umoja Biopharma, Inc.] |
|
|
|
|
| September 19 – 20, 2022 Vejle, Denmark |
|
|
|
|
|
| National University of Ireland Galway – Galway, Ireland |
|
|
|
| Icahn School of Medicine at Mount Sinai – New York, New York, United States |
|
|
|
| Wayne State University – Detroit, Michigan, United States |
|
|
|
| Baylor College of Medicine – Houston, Texas, United States |
|
|
|
| Novo Nordisk – Fremont, California, United States |
|
|
|
|